Together, these results highlight that BMI1 is a relevant mediator of SOX9 in promoting tumor malignancy and show the importance of this axis in cancer progression, thus providing new therapeutic possibilities, such as BMI1 inhibition, a strategy that is being currently evaluated in different cancer clinical trials. This evidence concerns the gene SOX9 and cancer.